StockNews.AI
DXCM
StockNews.AI
15 hrs

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM

1. Pomerantz LLP is investigating DexCom for potential securities fraud. 2. A report claims unauthorized changes led to inaccurate glucose readings. 3. DexCom's stock fell 11.76% following allegations of user hospitalizations. 4. Investors are encouraged to participate in a class action lawsuit. 5. The implications of the report could affect DexCom's market reputation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock drop and serious allegations suggest profound risk. Historical instances, such as medical device recalls, have led to long-term devaluation for similar companies.

How important is it?

The allegations directly link to product safety, a critical aspect for investor confidence. Legal challenges can create lasting financial implications.

Why Long Term?

The ongoing investigation may lead to prolonged reputational damage and financial consequences. Long-term trust issues with investors and patients can persist even after resolving current concerns.

Related Companies

ABTMDTBAYER
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether DexCom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 18, 2025, Hunterbrook Media (“Hunterbrook”) published a short report entitled “Dexcom’s Fatal Flaws”. The Hunterbrook report alleged, among other things, that Dexcom “made an unauthorized design change to a key component of the G7”, the Company’s continuous glucose monitoring system for diabetes management, and that “G7 users have been hospitalized and died” following inaccurate glucose readings from G7 devices.  On this news, Dexcom’s stock price fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News